Close
Novotech
Jabsco PureFlo 21 Single Use

Production & Manufacturing

Sustainable Sterile Manufacturing: Innovations in Injectable and Vaccine Production

The pharmaceutical industry faces an unprecedented convergence of pressures: escalating patient demand for complex biotherapeutics, environmental imperatives to minimize waste and energy consumption, and regulatory frameworks increasingly demanding advanced contamination control and process transparency. Sustainable sterile manufacturing has emerged...

CRISPR and Gene Editing: Next-Gen Manufacturing Impacts

The pharmaceutical and biotechnology industries are experiencing a profound technological revolution driven by CRISPR-Cas9 and emerging gene editing technologies that fundamentally alter how therapeutic agents are developed and manufactured. Gene editing pharma manufacturing represents far more than incremental improvement...

Precision Medicine Manufacturing: From Large-Scale to Patient-Centric Production

The pharmaceutical industry is experiencing a fundamental shift away from the traditional “blockbuster drug” model toward increasingly sophisticated precision medicine manufacturing strategies that prioritize individual patient needs over mass-market volume. This transformation represents far more than a simple adjustment...

AI-Enabled Supply Chain Resilience in Pharmaceutical Manufacturing

Pharmaceutical supply chains are fundamentally evolving as global disruptions, regulatory demands, and patient expectations converge to redefine how drugs reach the market. In today’s environment, pharmaceutical supply chain resilience depends not only on physical infrastructure and traditional logistics but...

Eli Lilly Commits $1.2bn to Modernize Puerto Rico Manufacturing

Governor Jenniffer A. González Colón, along with Sebastián Negrón Reichard, the Economic Development and Commerce Secretary, has announced that Eli Lilly and Company, also known as Lilly, is going to invest over $1.2bn to modernize Puerto Rico operations. This...

CDMOs Must Reorganize to Maximize Revenue and Competitiveness

Pharmaceutical businesses increasingly outsource their product development and manufacture to Contract Development and manufacture Organizations (CDMOs), which operate in a fragmented sector that is experiencing significant restructuring. However, a lot of CDMOs put their competitiveness at risk by not...

Investments in the U.S. of Over $70bn Announced by Merck

It is well to be noted that in 2025, a minimum of 14 major pharmaceutical companies across the world went ahead and announced plans to broaden their manufacturing presence in the U.S. so as to lessen the supply chain...

Subscribe

- Never miss a story with notifications

- Gain full access to our premium content

- Browse free from any location or device.

Must read

Translate »